First CAR-T therapy to target BCMA gets FDA nod – Nature
The first CAR-T immunotherapy directed against BCMA (idecabtagene vicleucel) for patients with relapsed or refractory multiple myeloma developed by partners Bristol Myers Squibb and bluebird bio was approved by the U.S. Food and Drug Administration on March 26, 2021. This therapy recognizes and binds BCMA (B cell maturation antigen) which is a cell surface protein […]
